The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...
Clinical Trials Arena on MSN13d
GSK reports positive outcomes from two Phase III trials of treatment for CRSwNPSecondary endpoint analyses from the trials showed 'significant improvements' in patients treated with the antibody.
Amgen and AstraZeneca have reported complete outcomes from the registrational Phase III WAYPOINT trial of Tezspire ...
Upstream Bio, Inc. announced the completion of patient enrollment in its Phase 2 clinical trial for verekitug in patients with chronic rhinosinusitis with nasal polyps (CRSwNP), projecting to ...
Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...
With Sunday’s Academy Awards ceremony in the rearview mirror, GSK is looking ahead to a potential blockbuster premiere of its ...
FDA reviews GSK depemokimab for asthma and CRSwNP, with a decision expected by December 2025. Phase 3 data shows improvements ...
“We closed 2024 and started 2025 with strong continued momentum, marked by the successful completion of enrollment in our Phase 2 clinical trial of verekitug in patients with CRSwNP in January 202 ...
We closed 2024 and started 2025 with strong continued momentum, marked by the successful completion of enrollment in our Phase 2 clinical ...
Research and development expenses were $21.8 million for the quarter ended December 31, 2024, compared to $11.6 million for the same period in 2023. The increase of $10.2 million was primarily driven ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback